To our knowledge, this study is the first to assess MRI changes following IDH inhibition as early as 3–6 weeks following initial treatment, so previous clinical studies describing tumor shrinkage in glioma patients19,20 may not have taken into consideration these early, transient changes. This evidence concerns the gene IDH2 and central nervous system cancer.